Posts Tagged ‘Supreme Court’

Supreme Court Decides Bowman v. Monsanto for Monsanto

Wednesday, May 15th, 2013

On May 13th, a unanimous Court found that the doctrine of patent exhaustion “does not allow the purchaser to make new copies of the patented invention.” [A copy of decision is at the end of this post.] In this case, the patented invention was a soybean seed obtained from a plant that had been genetically altered so that it is resistant (“survives exposure”) to the herbicide glyphosate. I know that this is “yesterday’s news” by now, but I need a break from plumbing the depths of CLS v. Alice, so I thought I would offer a few observations. (I also did posts when the Fed. Cir. ruling came down, when the Supreme Court granted cert. and when oral argument was heard.)

At least this was a “patent friendly” decision, and the Court even spent some time discussing its relationship with J.E.M. v. Pioneer Hi-Bred, 534 U.S. 124 (2001) in which a divided Supreme Court held that utility patents were available for plants, despite the protections offered by Plant Variety Protection Act Certificates (PVPA certificates). Slip op. at 7. In that decision, the Court held that “only a patent holder (not a certificate holder) could prohibit ‘[a] farmer who legally purchases and plants’ a protected seed from saving harvested seed ‘for replanting’…(noting that the Patent Act, unlike the PVPA contains ‘no exemptio[n]’ for ‘saving seed’).”

(more…)

CLS Bank v. Alice Corp. (Part 2)

Tuesday, May 14th, 2013

I hope that some of my loyal readers noticed that my last post on CLS was incomplete, since it did not elaborate on the rationale for the decision(s) arrived at by the majority, either directly or by default.

The first 23 pages of the  opinion, written by Judge Lourie, joined by Dyk, Prost, Reyna and Wallace, mostly plods down the well-worn legal trail of Benson, Flook, Diehr, Bilski and now, Mayo v. Prometheus. I read it mostly looking for something new, perhaps a hint of what additional material would render a claim reciting a law of nature patentable.

For example, for some time I have wondered in print what feature in Diehr distinguished the patent-eligible curing process from the patent-ineligible one in Flook. In Parker v. Flook, the Supreme Court held: “If a claim is directed essentially to a method of calculating, using a mathematical formula, even if the solution is for a specific purpose, the claimed method is nonstatutory.” Slip op. at 12. This is a much finer filter than one might expect , since the Flook process was drawn to the catalytic chemical conversion of hydrocarbons, but the Court tossed it into the dumpster of “abstract ideas” anyway. Judge Lourie noted that the Supreme Court had started from the posture that the case must be treated as though the abstract principle or mathematical formula were well known. If so, then the claim must contain “some other inventive concept in its application.”

(more…)

Myriad Argued Before The Supreme Court – Some Snippets

Wednesday, April 17th, 2013

I confess that I’ve become addicted to this case and just finished all 63 pages of the transcript of the oral argument that took place on Monday. I won’t try to summarize it, but rather will try to review some trends.

1)  Four of the Justices (Scalia, Kennedy, Kagan and Roberts) all expressed concern that ruling that isolated DNA is not patent-eligible would discourage investment in the research needed to lead to further useful inventions based on isolated genes. The question is, of course, how concerned are they? However Hansen, arguing for Myriad was questioned about this early in his time slot.

(more…)

Patents4Life is Four Years Old

Tuesday, March 26th, 2013

On March 24th, Patents4Life forgot to celebrate its 4th anniversary. On March 24, 2009, I started the blog (or is it “blawg”) by posting three articles on fairly recent Fed. Cir. decisions. One of the articles discussed the application of the then-recent “Bilski test” to the claims in suit in Classen v. Biogen (2008 WL 5273107) which involved a method of developing improved immunization schedules. The summary affirmance of the district court’s decision was based on the “machine or transformation test” developed in Bilski. Since at least one of the claims recited immunizing subjects, I wrote:

“The Bilski standard, now being applied in the area of biomedical technology, poses a significant threat to the viability of patents claiming diagnostic methods.”

(more…)